Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment

References

• VaupelPMayerAHöckelMTumor hypoxia and malignant progressionMethods Enzymol200438133535415063685
   PubMed Web of Science ®Google Scholar
• LessJRPosnerMCSkalakTCWolmarkNJainRKGeometric resistance and microvascular network architecture of human colorectal carcinomaMicrocirculation19974125339110281
   PubMed Web of Science ®Google Scholar
• SiemannDWThe unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting AgentsCancer Treat Rev2011371637420570444
   PubMed Web of Science ®Google Scholar
• VaupelPHöckelMMayerADetection and characterization of tumor hypoxia using pO2 histographyAntioxid Redox Signal2007981221123517536958
   PubMed Web of Science ®Google Scholar
• ZhuWDongZFuTModulation of Hypoxia in Solid Tumor Microenvironment with MnO2 Nanoparticles to Enhance Photodynamic TherapyAdv Funct Mater2016263054905498
   Web of Science ®Google Scholar
• MoulderJERockwellSHypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing dataInt J Radiat Oncol Biol Phys19841056957126735758
   PubMed Web of Science ®Google Scholar
• ZengWLiuPPanWSinghSRWeiYHypoxia and hypoxia inducible factors in tumor metabolismCancer Lett20153562 Pt A26326724508030
   PubMed Web of Science ®Google Scholar
• DhaniNFylesAHedleyDMilosevicMThe clinical significance of hypoxia in human cancersSemin Nucl Med201545211012125704384
   PubMed Web of Science ®Google Scholar
• Kizaka-KondohSKonse-NagasawaHSignificance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxiaCancer Sci200910081366137319459851
   PubMed Web of Science ®Google Scholar
• SchaferRGmitroAFDynamic oxygenation measurements using a phosphorescent coating within a mammary window chamber mouse modelBiomed Opt Express20156263965025780753
   PubMed Web of Science ®Google Scholar
• KitajimaKMurphyRCNathanMASugimuraKUpdate on positron emission tomography for imaging of prostate cancerInt J Urol2014211122323991644
   PubMed Web of Science ®Google Scholar
• SpickCHerrmannKCzerninJEvaluation of Prostate Cancer with 11C-Acetate PET/CTJ Nucl Med201657Suppl 330S37S27694168
   PubMedGoogle Scholar
• WhiteDAZhangZLiLDeveloping oxygen-enhanced magnetic resonance imaging as a prognostic biomarker of radiation responseCancer Lett20163801697727267808
   PubMed Web of Science ®Google Scholar
• O’ConnorJPBoultJKJaminYOxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer ModelsCancer Res201676478779526659574
   PubMed Web of Science ®Google Scholar
• HöckelMVaupelPTumor hypoxia: definitions and current clinical, biologic, and Molecular AspectsJ Natl Cancer Inst200193426627611181773
   PubMedGoogle Scholar
• RockwellSDobruckiITKimEYMarrisonSTVuVTVtVHypoxia and radiation therapy: past history, ongoing research, and future promiseCurr Mol Med20099444245819519402
   PubMed Web of Science ®Google Scholar
• GrayLHCongerADEbertMHornseySScottOCThe concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapyBr J Radiol19532631263864813106296
   PubMed Web of Science ®Google Scholar
• DangJHeHChenDYinLManipulating tumor hypoxia toward enhanced photodynamic therapy (PDT)Biomater Sci2017581500151128681887
   PubMed Web of Science ®Google Scholar
• MoghissiKDixonKGibbinsSA Surgical View of Photodynamic Therapy in Oncology: A ReviewSurg J (N Y)201511e1e1528824964
   PubMedGoogle Scholar
• TeicherBAHoldenSAAl-AchiAHermanTSClassification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcomaCancer Res19905011333933442334928
   PubMed Web of Science ®Google Scholar
• TeicherBALazoJSSartorelliACClassification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cellsCancer Res198141173817448778
   PubMed Web of Science ®Google Scholar
• StreseSFryknäsMLarssonRGullboJEffects of hypoxia on human cancer cell line chemosensitivityBMC Cancer20131333123829203
   PubMed Web of Science ®Google Scholar
• SunSLeeDLeeNPHyperoxia resensitizes chemoresistant human glioblastoma cells to temozolomideJ Neurooncol2012109346747522763762
   PubMed Web of Science ®Google Scholar
• WoutersAPauwelsBLardonFVermorkenJBReview: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditionsOncologist200712669071217602059
   PubMed Web of Science ®Google Scholar
• BakerAFKohMYWilliamsRRIdentification of thioredoxin-interacting protein 1 as a hypoxia-inducible factor 1 alpha-induced gene in pancreatic cancerPancreas200836217818618376310
   PubMed Web of Science ®Google Scholar
• CheeverMAHiganoCSPROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineClin Cancer Res201117113520352621471425
   PubMed Web of Science ®Google Scholar
• AsciertoPAAddeoRCartenìGThe role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014J Transl Med20141229125331657
   PubMed Web of Science ®Google Scholar
• MarkovicSNKumarABTherapeutic Targets of FDA-Approved Immunotherapies in OncologyThe Basics of Cancer ImmunotherapyDongHMarkovicSNChamSpringer International Publishing20182137
   Google Scholar
• HodiFSO’DaySJMcdermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• HamidORobertCDaudASafety and tumor responses with lambrolizumab (anti-PD-1) in melanomaN Engl J Med2013369213414423724846
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• JuneCHO’ConnorRSKawalekarOUGhassemiSMiloneMCCAR T cell immunotherapy for human cancerScience201835963821361136529567707
   PubMed Web of Science ®Google Scholar
• LeoneRDHortonMRPowellJDSomething in the air: hyperoxic conditioning of the tumor microenvironment for enhanced immunotherapyCancer Cell201527443543625873169
   PubMed Web of Science ®Google Scholar
• HatfieldSMSitkovskyMA2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancerCurr Opin Pharmacol201629909627429212
   PubMed Web of Science ®Google Scholar
• SitkovskyMVHatfieldSAbbottRBelikoffBLukashevDOhtaAHostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologistsCancer Immunol Res20142759860524990240
   PubMed Web of Science ®Google Scholar
• FacciabeneAPengXHagemannISTumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cellsNature2011475735522623021753853
   PubMed Web of Science ®Google Scholar
• HatfieldSMKjaergaardJLukashevDImmunological mechanisms of the antitumor effects of supplemental oxygenationSci Transl Med20157277277ra230
   Web of Science ®Google Scholar
• BrownJMTumor hypoxia in cancer therapyMethods Enzymol200743529732117998060
   PubMed Web of Science ®Google Scholar
• YehJJKimWYTargeting tumor hypoxia with hypoxia-activated prodrugsJ Clin Oncol201533131505150825800764
   PubMed Web of Science ®Google Scholar
• LinAJCosbyLAShanskyCWSartorelliACPotential bioreductive alkylating agents. 1. Benzoquinone derivativesJ Med Chem19721512124712524635968
   PubMed Web of Science ®Google Scholar
• GuiseCPMowdayAMAshoorzadehABioreductive prodrugs as cancer therapeutics: targeting tumor hypoxiaChin J Cancer2014332808623845143
   PubMed Web of Science ®Google Scholar
• BrizelDMLinSJohnsonJLBrooksJDewhirstMWPiantadosiCAThe mechanisms by which hyperbaric oxygen and carbogen improve tumour oxygenationBr J Cancer1995725112011247577456
   PubMed Web of Science ®Google Scholar
• JainKKPhysical, physiological, and biochemical aspects of hyperbaric oxygenationJainKKTextbook of Hyperbaric MedicineChamSpringer International Publishing20171122
   Google Scholar
• ThewsOVaupelPSpatial oxygenation profiles in tumors during normo- and hyperbaric hyperoxiaStrahlenther Onkol20151911187588226135917
   PubMed Web of Science ®Google Scholar
• WatsonERHalnanKEDischeSHyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervixBr J Radiol197851611879887361144
   PubMed Web of Science ®Google Scholar
• CadeISMcEwenJBClinical trials of radiotherapy in hyperbaric oxygen at Portsmouth, 1964–1976Clin Radiol1978293333338417893
   PubMed Web of Science ®Google Scholar
• BeppuTKamadaKYoshidaYAraiHOgasawaraKOgawaAChange of oxygen pressure in glioblastoma tissue under various conditionsJ Neurooncol2002581475212160140
   PubMed Web of Science ®Google Scholar
• ChangCHHyperbaric oxygen and radiation therapy in the management of glioblastomaNatl Cancer Inst Monogr197746163169206835
   PubMedGoogle Scholar
• KohshiKKinoshitaYTerashimaHKondaNYokotaASoejimaTRadiotherapy after hyperbaric oxygenation for malignant gliomas: a pilot studyJ Cancer Res Clin Oncol1996122116766788898978
   PubMed Web of Science ®Google Scholar
• StępieńKOstrowskiRPMatyjaEHyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumoursMed Oncol201633910127485098
   PubMed Web of Science ®Google Scholar
• HatfieldSMKjaergaardJLukashevDSystemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protectionJ Mol Med (Berl)201492121283129225120128
   PubMed Web of Science ®Google Scholar
• KhandelwalSRKavanaghBDLinPSRSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H miceBr J Cancer1999795–681482010070874
   PubMed Web of Science ®Google Scholar
• SuhJHSteaBNabidAPhase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastasesJ Clin Oncol200624110611416314619
   PubMed Web of Science ®Google Scholar
• SuhJHSteaBTankelKResults of the Phase III ENRICH (RT-016) Study of Efaproxiral Administered Concurrent with Whole Brain Radiation Therapy (WBRT) in Women with Brain Metastases from Breast CancerInt J Radiat Oncol Biol Phys2008721S50S51
   Web of Science ®Google Scholar
• GainerJLSheehanJPLarnerJMJonesDRTrans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiformeJ Neurosurg2017126246046627177177
   PubMed Web of Science ®Google Scholar
• MurayamaCKawaguchiATIshikawaKLiposome-encapsulated hemoglobin ameliorates tumor hypoxia and enhances radiation therapy to suppress tumor growth in miceArtif Organs201236217017722339726
   PubMed Web of Science ®Google Scholar
• TeicherBAAraGHerbstRTakeuchiHKeyesSNortheyDPEG-hemoglobin: effects on tumor oxygenation and response to chemotherapyIn Vivo19971143013119292296
   PubMed Web of Science ®Google Scholar
• MoanNLLeungPNgSAbstract 4686: Omx a hypoxia modulator reverses the immunosuppressive glioblastoma microenvironment by stimulating T cell infiltration and activation that results in increased number of long-term survivorsCancer Res20177713 Supplement46864686
   Google Scholar
• JohnsonJLHOxygen carriers: are they enough for cellular support?LapchakPAZhangJHNeuroprotective Therapy for Stroke and Ischemic DiseaseChamSpringer International Publishing2017621640
   Google Scholar
• RiessJGUnderstanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen deliveryArtif Cells Blood Substit Immobil Biotechnol2005331476315768565
   PubMed Web of Science ®Google Scholar
• ChengYChengHJiangCPerfluorocarbon nanoparticles enhance reactive oxygen levels and tumour growth inhibition in photodynamic therapyNat Commun20156878526525216
   PubMed Web of Science ®Google Scholar
• RockwellSIrvinCGKelleyMEffects of hyperbaric oxygen and a perfluorooctylbromide emulsion on the radiation responses of tumors and normal tissues in rodentsInt J Radiat Oncol Biol Phys199222187931727131
   PubMed Web of Science ®Google Scholar
• RoseCLustigRMcintoshNTeicherBA clinical trial of Fluosol DA 20% in advanced squamous cell carcinoma of the head and neckInt J Radiat Oncol Biol Phys1986128132513273759553
   PubMed Web of Science ®Google Scholar
• EvansRGKimlerBFMorantzRAA phase I/II study of the use of Fluosol as an adjuvant to radiation therapy in the treatment of primary high-grade brain tumorsInt J Radiat Oncol Biol Phys19901924154202168356
   PubMed Web of Science ®Google Scholar
• HochbergFPradosMRussellCTreatment of recurrent malignant glioma with BCNU-fluosol and oxygen inhalation. A phase I–II studyJ Neurooncol199732145559049862
   PubMed Web of Science ®Google Scholar
• JohnsonJLDolezalMCKerschenAMatsunagaTOUngerECIn vitro comparison of dodecafluoropentane (DDFP), perfluorodecalin (PFD), and perfluoroctylbromide (PFOB) in the facilitation of oxygen exchangeArtif Cells Blood Substit Immobil Biotechnol200937415616219548131
   PubMed Web of Science ®Google Scholar
• JohnsonJLLeosRABakerAFUngerECRadiosensitization of Hs-766T Pancreatic Tumor Xenografts in Mice Dosed with Dode-cafluoropentane Nano-Emulsion-Preliminary FindingsJ Biomed Nanotechnol201511227428126349303
   PubMed Web of Science ®Google Scholar
• SheehanJShermanJCifarelliCEffect of trans sodium crocetinate on brain tumor oxygenation. Laboratory investigationJ Neurosurg2009111222622919326986
   PubMed Web of Science ®Google Scholar
• KochCJOpryskoPRShumanALJenkinsWTBrandtGEvansSMRadiosensitization of hypoxic tumor cells by dodecafluoropentane: a gas-phase perfluorochemical emulsionCancer Res200262133626362912097264
   PubMed Web of Science ®Google Scholar
• StuppRMasonWPvan den BentMJRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799615758009
   PubMed Web of Science ®Google Scholar
• CollingridgeDRPiepmeierJMRockwellSKniselyJPPolarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissueRadiother Oncol199953212713110665789
   PubMed Web of Science ®Google Scholar
• MeixensbergerJDingsJKuhnigkHRoosenKStudies of tissue PO2 in normal and pathological human brain cortexActa Neurochir Suppl19935958637906079
   PubMedGoogle Scholar
• RamplingRCruickshankGLewisADFitzsimmonsSAWorkmanPDirect measurement of pO2 distribution and bioreductive enzymes in human malignant brain tumorsInt J Radiat Oncol Biol Phys19942934274318005794
   PubMed Web of Science ®Google Scholar
• BluffJEBrownNJReedMWStatonCATissue factor, angiogenesis and tumour progressionBreast Cancer Res200810220418373885
   PubMed Web of Science ®Google Scholar
• OgiichiTHirashimaYNakamuraSEndoSKurimotoMTakakuATissue factor and cancer procoagulant expressed by glioma cells participate in their thrombin-mediated proliferationJ Neurooncol20004611910896200
   PubMed Web of Science ®Google Scholar
• MaityAPoreNLeeJSolomonDO’RourkeDMEpidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxiaCancer Res200060205879588611059786
   PubMed Web of Science ®Google Scholar
• PelesELidarZSimonAJGrossmanRNassDRamZAngiogenic factors in the cerebrospinal fluid of patients with astrocytic brain tumorsNeurosurgery2004553562567 discussion 567–56815335423
   PubMed Web of Science ®Google Scholar
• WachsbergerPBurdRDickerAPImproving tumor response to radiotherapy by targeting angiogenesis signaling pathwaysHematol Oncol Clin North Am20041851039105715474334
   PubMed Web of Science ®Google Scholar
• YaoXHPingYFChenJHProduction of angiogenic factors by human glioblastoma cells following activation of the G-protein coupled formylpeptide receptor FPRJ Neurooncol2008861475317611713
   PubMed Web of Science ®Google Scholar
• BristowRGHillRPHypoxia and metabolism. Hypoxia, DNA repair and genetic instabilityNat Rev Cancer20088318019218273037
   PubMed Web of Science ®Google Scholar
• UngerECA phase Ib/II clinical trial of a novel oxygen therapeutic in chemoradiation of glioblastoma2017 ASCO Annual MeetingJune 2 – June 6, 2017Chicago, IL, USA
   Google Scholar